The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor ?d T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC).
 
Sumanta Pal
Speakers' Bureau - IntrinsiQ; MJH Life Sciences; Peerview
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Helen Budworth
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
 
Xiaoyan Du
Employment - Adicet Bio; Bristol-Myers Squibb
Stock and Other Ownership Interests - Adicet Bio; Bristol-Myers Squibb
 
Shon Green
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
 
Kevin Nishimoto
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
Patents, Royalties, Other Intellectual Property - Adicet Bio
 
Jackie Kennedy-Wilde
Employment - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
Patents, Royalties, Other Intellectual Property - Adicet Bio
 
Blake Aftab
Employment - Adicet Bio; Amgen (I)
Leadership - Adicet Bio
Stock and Other Ownership Interests - Adicet Bio
Patents, Royalties, Other Intellectual Property - Adicet Bio; Atara Biotherapeutics; Fortis; Regents of the University of California; Sanofi
Travel, Accommodations, Expenses - Adicet Bio
 
Julia Maltzman
Employment - Adicet Bio; IconOVir Bio
Stock and Other Ownership Interests - Roche
Consulting or Advisory Role - Kamada (I); Qihan Biotech (I)
 
Gregory Vosganian
Employment - Adicet Bio; BeiGene; Kartos Therapeutics; Telios
Stock and Other Ownership Interests - Adicet Bio; BeiGene; Telios
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai